Bruker (NASDAQ:BRKR) Releases Earnings Results, Beats Expectations By $0.01 EPS

Bruker (NASDAQ:BRKR) announced its quarterly earnings data on Thursday. The medical research company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.01, Zacks reports. Bruker had a return on equity of 21.52% and a net margin of 9.41%. Bruker updated its FY 2025 guidance to 2.670-2.720 EPS.

Bruker Trading Down 1.0 %

NASDAQ:BRKR opened at $51.15 on Friday. Bruker has a 12 month low of $48.07 and a 12 month high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $7.75 billion, a P/E ratio of 24.59, a PEG ratio of 3.81 and a beta of 1.16. The firm has a fifty day simple moving average of $57.73 and a 200-day simple moving average of $60.71.

Insider Buying and Selling at Bruker

In other Bruker news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction on Monday, November 18th. The stock was bought at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. 28.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. TD Cowen decreased their target price on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Bank of America raised their target price on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Citigroup reduced their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research note on Thursday, December 5th. Finally, Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Bruker has an average rating of “Moderate Buy” and an average price target of $74.09.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.